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Background. Matrilysin, a secreted matrix metalloproteinase
and target gene of Wnt signaling, functions in epithelial re-
pair and host defense, but no role in renal injury has been
described.
Methods. Matrilysin expression was assessed in human kid-
ney specimens by immunohistochemistry, and in experimental
renal injury in mice by immunohistochemistry, Northern blot-
ting, and RNase protection assays (RPA). A relationship to
Wnt4, which is also induced in renal injury, was determined by
RPA and in situ hybridization.
Results. Matrilysin was not detected in the normal human
renal tubular epithelium by immunohistochemistry. However,
prominent staining was detected in sections from autosomal-
dominant polycystic kidney disease in the cyst lining epithelium,
atrophic tubules, and cyst micropolyps, and from hydronephro-
sis in dilated and atrophic tubules. Matrilysin expression was
also induced by acute folic acid nephropathy and unilateral
ureteral obstruction (UUO) in the mouse, and expression in-
creased as acute injury progressed to tubulointerstitial fibrosis.
Matrilysin staining was primarily localized to epithelium of dis-
tal tubule/collecting duct origin in both human and murine re-
nal disease. Wnt signaling can induce matrilysin expression, and
we found that the pattern of matrilysin expression during pro-
gression of renal fibrosis in the mouse after UUO or folic acid
nephropathy, and in the jck model of murine polycystic kidney
disease, closely paralleled that of Wnt4.
Conclusion. These observations suggest that matrilysin may
have a role in renal tubular injury and progression of tubuloint-
erstitial fibrosis, and that Wnt4 may regulate matrilysin expres-
sion in the kidney.
The renal epithelium is damaged in various pathologic
processes, including acute tubular necrosis, obstructive
uropathy, and cystic degeneration. The initial response
to tubular injury is a regenerative process to restore ep-
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ithelial structure and functional integrity that is character-
ized by transient de-differentiation of tubular epithelial
cells, migration and proliferation, and re-differentiation
into an intact epithelium [1]. Renal tubular injury also
stimulates inflammation and interstitial fibrosis. If repair
is incomplete, progressive interstitial fibrosis leads to dis-
ruption of tubulointerstitial architecture and loss of renal
tubular function [2]. Both repair and fibrosis involve de-
position and turnover of extracellular matrix (ECM), and
it has been proposed that the matrix accumulation seen
in fibrosis results from increased deposition coupled with
decreased turnover [3]. Although several proteolytic en-
zymes have been suggested to be involved in regulating
renal responses to injury, the functions of specific pro-
teinases in the kidney remain largely unknown.
The matrix metalloproteinases (MMPs) are a family of
zinc-containing enzymes with proteolytic activity against
a wide range of extracellular proteins [4]. MMP expres-
sion is typically limited to tissue remodeling associated
with normal and abnormal biological processes, such as
development, involution, inflammation, tumor growth,
and repair. Although MMPs are expressed in normal
and injured kidneys, defining roles for specific MMPs
has been difficult as the levels of individual enzymes
have been reported to be increased, decreased, or un-
changed, depending on the disease model [3]. Although
matrilysin (MMP-7) may be expressed at low levels by
noninjured, noninflamed mucosal epithelia in many adult
human tissues [5, 6], its expression is increased in injured
epithelium of gastrointestinal tract and lung [7, 8]. For ex-
ample, matrilysin is prominently expressed by airway and
alveolar epithelium in a variety of human lung diseases,
such as cystic fibrosis and pulmonary fibrosis [8–11]. Al-
though first isolated from cultured mesangial cells [12],
matrilysin expression has not been reported in the normal
or diseased kidney.
Wnt-4, a secreted glycoprotein required for nephro-
genesis and normal renal tubule development [13, 14],
is expressed in the normal mouse adult kidney only
in the most distal papillary collecting duct epithelium,
but is induced throughout the collecting duct epithelium
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and in surrounding interstitial cells after renal injury
[15]. Activation of the canonical Wnt signaling pathway
leads to translocation of cytosolic b-catenin to the nu-
cleus, where it binds to transcription factors of the lym-
phocyte enhancer-binding factor-1/T-cell factor pathway
(Lef-1/TCF) to regulate expression of target genes, in-
cluding matrilysin [16, 17]. Because Wnt4 is activated
in tubulointerstitial disruption leading to renal fibrosis,
and can stimulate the b-catenin pathway [15], and ma-
trilysin is a target of the Wnt/b-catenin/TCF pathway,
we assessed matrilysin expression in human renal tubu-
lar disease and in mouse models of experimental renal
tubular injury.
METHODS
Immunohistochemistry
Blocks of formalin-fixed, paraffin-embedded normal
and diseased human kidney tissue were obtained from
the Department of Pathology, Washington University
School of Medicine. Specimens were identified by the
diagnosis recorded in the archive and included normal
adult kidney (N =3), autosomal-dominant polycystic kid-
ney disease (N = 6), hydronephrosis with fibrosis (N =
4), and autosomal-recessive polycystic kidney disease
(N = 2). Sections were stained for matrilysin as described
[8]. Polyclonal antibodies against the catalytic domain of
human matrilysin [6] and full-length mouse matrilysin
[18] were previously generated in our laboratory. For
mouse tissues, 6-lm frozen sections were air dried, fixed in
acetone for 10 minutes at −20◦C and methanol for 6 min-
utes at −20◦C, blocked for 1 hour at room temperature
with TBST (25 mmol/L Tris-HCL, pH 7.5, 150 mmol/L
NaCl, 0.1% Tween 20) containing 1% bovine serum
albumin (BSA) and 2% goat serum, and then incu-
bated with rabbit antimouse matrilysin antiserum for
1 hour at 37◦C, followed by incubation with secondary
antibodies for 1 hour at 37◦C. Alexa 488-conjugated
antirabbit immunoglobulin (Ig)G (Molecular Probes,
Eugene, OR, USA) was used at the manufacturer’s rec-
ommended concentrations. For folic acid treated mice,
frozen sections were fixed in Bouin’s fluid and methanol,
and endogenous peroxidases were quenched with 0.6%
H2O2 in methanol, and blocked as above. After incuba-
tion with primary antibody, staining was visualized with
a Vectastain Elite kit (Vector Laboratories, Burlingame,
CA, USA) and True Blue substrate (KPL, Gaithersburg,
MD, USA). For lectin staining, fixed, rehydrated sections
were incubated with rhodamine-conjugated peanut ag-
glutinin (arachis hypogaea) (Vector Laboratories) or flu-
orescein isothiocyanate (FITC)-conjugated winged pea
(lotus tetragonolobus) lectin (Vector Laboratories) at
10 lg/mL for 30 minutes at 37◦C. Indirect immunoflu-
orescence and confocal laser-scanning microscopy were
used to image fluorescent markers.
Mouse renal damage models
The Washington University Institutional Animal Care
and Use Committee approved all animal experiments.
Unilateral ureteral obstruction (UUO) was performed on
anesthetized C57Bl/6J or FVB/N mice of 6 to 10 weeks of
age by surgical cautery of the left ureter approximately
15 mm from the renal pelvis. Obstructed kidneys were
harvested at 1, 2, 4, 5, 7, 14, or 28 days after obstruction.
Uninjured kidneys were harvested from seven-week-old
mice. Kidneys were snap-frozen in liquid nitrogen for
RNA isolation with an RNeasy kit (Qiagen, Valencia,
CA, USA) or frozen in OCT medium for in situ hybridiza-
tion. For Northern analysis, total kidney tissue was ex-
tracted with RNA STAT-60 (Tel-test, Friendswood, TX,
USA) according to manufacturer’s protocol.
Mice homozygous for the juvenile cystic kidney (jck)
mutation on the C57Bl/6J background were obtained
from Jackson Laboratory (Bar Harbor, ME, USA). Kid-
neys from sixteen-week-old jck mice were used for in situ
hybridization.
Folic acid nephropathy was induced by intraperitoneal
injection of folic acid (250 mg/kg in 150 mmol/L sodium
carbonate). All mice treated with this dose had a rise
in serum creatinine of at least 2-fold above baseline at
48 hours, as assessed with creatinine kit 555-A (Sigma-
Aldrich, St. Louis, MO, USA). Kidneys were harvested
at 0, 24, 48, 72, and 96 hours, and at 6 and 16 days after
folic acid treatment.
RNA analysis
For Northern analysis, total RNA (10 lg) was re-
solved by electrophoresis, transferred to Hybond+
nylon membranes (Amersham Pharmacia Biotech,
Buckinghamshire, UK), and ultraviolet (UV) cross-
linked. Equivalent loading and integrity of RNA was
confirmed by ethidium bromide staining of 18S and 28S
rRNA bands. Gel-purified cDNA probes for mouse ma-
trilysin were labeled by random priming, hybridized to
membranes overnight, and visualized by autoradiogra-
phy and quantified using NIH Image software.
In situ hybridization was performed as described [15].
The template used to produce murine Wnt4 riboprobes
was a gift from Andy McMahon. The in situ Wnt4 anti-
sense riboprobe spans nucleotides 803 to 366 (Genbank
NM009523). Specificity of the Wnt4 probe was confirmed
by control experiments performed with a Wnt4 sense
probe that did not hybridize to mouse tissues ([19] and
data not shown). The murine MMP7 template was sub-
cloned from the Image Consortium EST clone AI316399.
This clone was digested with XbaI and BalI and sub-
cloned into EcoRV and XbaI sites of pZero2.1 (Invit-
rogen, Carlsbad, CA, USA). The MMP7 antisense ribo-
probe for in situ and RPA spans nucleotides 326 to 699
(Genbank L36244).
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For ribonuclease protection assays (RPA), radio-
labeled antisense riboprobes were transcribed using
linearized cDNA templates, 32P-a-UTP (Amersham
Pharmacia Biotech), and the Promega (Madison, WI)
in vitro transcription system. The Wnt4 RPA riboprobe
spans nucleotides 803 to 676 (Genbank NM009523). The
mouse cyclophilin A gene template was purchased from
Ambion (Austin, TX, USA). Five lg of RNA from each
sample was used for RPA as described [15], with one
modification: following overnight hybridization at 45◦C,
300 lL of RNAse digestion buffer [25 lg RNase A
(Roche, Indianapolis, IN, USA); 250 U RNAse T1
(Roche); 10 mmol/L TRIS, pH 7.5; 5 mmol/L EDTA, pH
8.0; 350 mmol/L NaCl] was added to each reaction, fol-
lowed by incubation at 37◦C for 30 minutes. Radioactivity
was visualized with a Molecular Dynamics storage phos-
phorimaging system and quantified using NIH Image. At
each time point, at least three obstructed kidneys were
analyzed by RPA, and at least two obstructed kidneys
were examined by in situ hybridization.
For semiquantitative reverse transcriptase-polymerase
chain reaction (RT-PCR) analysis, 1 lg of total kidney
RNA was reverse transcribed with random primers
using Sigma Enhanced Avian RT kit followed by PCR
according to manufacturer’s protocol. The primers used
for specific PCR amplification were as follows: For mouse
matrilysin: forward, 5′-ACAGGTGCAGCTCAGGAA
GG-3′; reverse, 5′-GTGAAGGACGCAGGAGTGAA
C-3′ (PCR product 292 bp); for Wnt4: forward, 5′-AGCC
GGGCACTCATGAATCTTCACAACA-ACGAGG-3′;
reverse, 5′-TCATCTGTATGTGGCTTGAACTGTGC
ATTCCGAG-3′ (PCR product 260 bp); for b-actin: for-
ward, 5′-TTTTCCAGCCTTCCTTCTTGGGTATGGA
A-TCCTGTG-3′, reverse, 5′- ATCTGCTGGAAGGTG
GACAGTGAGGCCAGGATGGAG-3′ (PCR product
283 bp). The primers for each gene were designed from
different exons so as to distinguish between products
made by genomic DNA amplification versus cDNA am-
plification, and control PCR reactions were done without
template cDNA (data not shown). PCR products were
resolved on agarose gels, stained with ethidium bromide,
and recorded using a Kodak EDAS 290 gel imaging
system (Rochester, NY, USA).
RESULTS
Matrilysin expression in human renal tubular disease
Matrilysin expression in human renal tubular disease
was assessed by immunohistochemistry. Matrilysin pro-
tein was not detected in normal adult human kidney
(Fig. 1A). In samples of autosomal-dominant polycystic
kidney disease (ADPKD), prominent staining for ma-
trilysin was detected in cyst-lining epithelium and at-
rophic tubules (Fig. 1B and D). Lectin staining with
peanut agglutinin, a marker for distal tubule/collecting
duct epithelium [20], showed that matrilysin protein was
detected only in epithelium of distal nephron origin
(Fig. 1C). Staining of serial sections with lotus
tetragonolobus lectin, a proximal tubule marker, did not
overlap with matrilysin staining (data not shown). In at-
rophic tubules, matrilysin staining was primarily associ-
ated with the apical/lumenal surface of the epithelium and
with intralumenal proteinaceous debris (Fig. 1B and E).
In cyst-lining epithelium, matrilysin was diffuse through-
out the cytoplasm (Fig. 1D). Matrilysin staining was also
seen in the epithelium of micropolyp outgrowths from
the cyst wall (Fig. 1F). In samples of hydronephrosis,
matrilysin staining was seen in atrophic tubules and in
cells lining some dilated tubules (Fig. 1G and H). As in
ADPKD, matrilysin staining in atrophic tubules was pri-
marily apical/lumenal. No immunoreactivity was seen in
specimens processed with control rabbit IgG (Fig. 1I).
Matrilysin was not detected in samples of autosomal-
recessive polycystic kidney disease (ARPKD) (data not
shown). As in other tissues, matrilysin immunostaining
was primarily restricted to epithelial cells, and was not
seen in interstitial cells or inflammatory cells.
Matrilysin expression in experimental acute renal
tubular injury
Mouse models of renal tubule injury were used to de-
termine if induction of matrilysin expression is part of
the epithelial response to injury in the kidney. Matrilysin
mRNA expression was assessed by Northern analysis in
folic acid nephropathy in the mouse, a model of acute
renal tubular injury. A single intraperitoneal injection of
folic acid (250 mg/kg) causes folate crystallization in the
distal tubule, and induces an acute renal tubular injury
characterized by extensive cell death within 24 hours,
followed by cellular de-differentiation and proliferation
peaking 48 to 72 hours after injection [21]. C57Bl6 mice
were treated with folic acid and sacrificed at 0, 24, 48, 72,
and 96 hours, and at 6 days after treatment. Matrilysin
is not developmentally expressed in the mouse kidney
[5], and only low levels of matrilysin mRNA were de-
tected in normal, uninjured adult mouse kidney (Fig. 2A).
Matrilysin mRNA was detected as early as 24 hours af-
ter folic acid injection and continued to increase 72 to
96 hours after treatment. In this model, some animals de-
velop a more severe and progressive renal injury, with
interstitial inflammation beginning at 4 days after injury
[22], and tubulointerstitial fibrosis apparent at 7 to 14 days
[15]. We found that in some animals, matrilysin mRNA
was barely detectable 5 days after folic acid treatment,
but in other animals, injury was progressive, and ma-
trilysin expression continued to increase at 6 days after
initial injury (Fig. 2A and B). Matrilysin induction was not
detected in the calcium carbonate vehicle-injected ani-
mals. Although the extent of injury varies from animal to
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Fig. 1. Matrilysin expression in human renal tubular disease. Sections of human kidney were stained for matrilysin protein (peroxidase). (A)
Matrilysin was not detected in normal adult human kidney tissue. In autosomal-dominant polycystic kidney disease (ADPKD), matrilysin was
detected in (B and D) epithelial cells lining cysts (arrowheads), (B and E) atrophic tubules (arrows), and (F) cyst micropolyps. (C) Staining of serial
section from (B) with peanut agglutinin (arachis hypogaea), a marker for distal tubule/collecting duct epithelium, showed that matrilysin staining
was associated only with tubules of distal nephron origin. (G and H) In hydronephrosis, matrilysin staining was detected in cells lining dilated and
atrophic tubules (arrows). Images in (E) and (H) are higher magnification images of sections in (B) and (G), respectively. (I) No staining is detected
in ADPKD specimen incubated with rabbit IgG control. (Scale bars: A and G = 100 lm; others = 50 lm).
animal, matrilysin expression was consistently induced in
all folic acid–treated animals by 48 hours. Furthermore,
the degree of matrilysin mRNA induction correlated with
the severity of renal tubular dysfunction as assessed by
serum creatinine levels (Fig. 2C).
To determine the cellular source of matrilysin in the
kidney, matrilysin protein expression in folic acid–injured
kidneys was assessed by immunohistochemistry. Consis-
tent with Northern data, matrilysin protein was not seen
in normal adult mouse kidney (Fig. 3A). At 24 to 72 hours
after folic acid injection, matrilysin protein was detected
in the epithelium of dilated renal tubules primarily in the
renal medulla and occasionally in the cortex (Fig. 3B and
C). Similar to the matrilysin staining pattern in human
kidney tissues, matrilysin staining was localized to the
apical/luminal aspect of cells lining dilated tubules, pro-
teinaceous debris within the tubule lumen, and also to
the intracellular compartment. Peanut lectin staining in-
dicated that matrilysin was expressed in epithelium of dis-
tal tubule/collecting duct origin (Fig. 3D to I). Because of
the patchy nature of folic acid injury, not all of the peanut
lectin–labeled tubules stain positive for matrilysin.
Because folic acid–induced renal injury is variable, ma-
trilysin expression was evaluated after UUO, a more
consistent and reproducible model of renal injury. UUO
produces complete upper urinary tract obstruction,
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Fig. 2. Matrilysin expression is induced in acute folic acid nephropa-
thy in the mouse. Northern analysis for matrilysin in total kidney RNA
isolated from mice treated with intraperitoneal folic acid (250 mg/kg)
in calcium carbonate vehicle. Ethidium bromide stained 18S and 28S
rRNA are shown as a loading control. Mouse small intestine (SI) is
shown as positive control. (A) Matrilysin mRNA is not detected in con-
trol vehicle treated animals, but is detected as early as 24 hours after
folic acid treatment and peaks at 48 to 72 hours. By 5 days, matrilysin
RNA is largely absent. (B) In some animals, a chronic injury devel-
ops, and matrilysin expression increases beyond 96 hours. (C) Relative
matrilysin expression assessed by Northern blotting was quantified by
densitometry and graphed in relation to serum creatinine. Severity of
renal dysfunction is variable but matrilysin expression correlates with
degree of creatinine elevation.
leading to an acute tubular injury followed by fibrosis in-
volving the entire kidney. Induction of matrilysin expres-
sion was detected at 2 days after UUO and continued to
increase at 5 days, when fibrosis begins (Fig. 4).
Association between matrilysin and Wnt4
Matrilysin is a target of the Wnt signaling pathway
[17], and Wnt4 is induced in kidneys after UUO and folic
acid nephropathy in both C57Bl6 and FVB/N mice [15].
Therefore, the temporal relationship between matrilysin
and Wnt4 induction after UUO was assessed by RNase
protection assay (RPA). FVB/N mice were subjected to
UUO and sacrificed at 0, 4, 7, 14, and 28 days after ob-
struction. Consistent with the Northern data for C57Bl6
mice, RPA showed that matrilysin mRNA expression was
induced by 4 days after injury. It then peaked at 14 days
and remained elevated at 28 days (Fig. 5A). The time
course of the increase in matrilysin expression paralleled
closely that of the increase in Wnt4 mRNA (Fig. 5B and
C). Levels of cyclophilin A mRNA, which is ubiquitously
expressed [23], remained constant. Because of the low
level of detectable Wnt4 in whole kidney total RNA early
after folic acid injury in C57Bl6 mice, we used semiquan-
titative RT-PCR, a more sensitive method, to assess Wnt4
and matrilysin mRNA expression in the same animals at
early time points. As reported by others, and as shown
in Figure 2, the severity of renal injury is variable after
folic acid treatment, and as predicted, the level of Wnt4
and matrilysin mRNA expression varied between ani-
mals. However, the pattern of Wnt4 induction correlated
with that of matrilysin (Fig. 5D).
Wnt4 expression was localized in relation to matrilysin
by in situ hybridization in samples of FVB/N mice. Con-
sistent with previous findings, at 14 days after UUO, Wnt4
was expressed in the inner medulla and in stripes that ex-
tend from the inner medulla into the cortex. Wnt4 was
also seen in the epithelium lining the dilated renal pelvis
(Fig. 6A). The pattern of matrilysin expression was nearly
identical to that of Wnt4, although the expression of ma-
trilysin was not as diffuse as that for Wnt4 mRNA in the
renal papilla (Fig. 6B). Specificity of the matrilysin probe
was confirmed by strong hybridization to small intestinal
tissue in which matrilysin is highly expressed [5] and lack
of hybridization to uninjured kidney (data not shown).
Early after obstruction, Wnt4 was expressed by tubular
epithelial cells, but by 14 days after obstruction, expres-
sion was also seen in peritubular fibroblasts [15]. Con-
sistent with the pattern of matrilysin expression seen in
human kidney tissue specimens, and in murine kidneys af-
ter folic acid treatment, immunofluorescence microscopy
for matrilysin at 14 days after UUO indicated that ma-
trilysin was localized primarily to tubular epithelium
(Fig. 6C and D).
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Fig. 3. Matrilysin localizes to distal nephron tubular epithelium in acute folic acid nephropathy. Sections of kidney from folic acid–treated mice
were assessed for matrilysin protein expression by immunohistochemistry (peroxidase/True Blue). (A) Matrilysin protein was not detected in
control vehicle-treated mouse kidney. (B) At 24 hours after folic acid treatment, matrilysin protein is detected in tubular epithelium. (C) Higher
magnification of a 72-hour specimen shows matrilysin staining associated with luminal surface of tubule epithelium and proteinaceous debris within
tubule (arrows). (D–I) Confocal immunofluorescence microscopy for matrilysin and peanut lectin (arachis hypogaea) superimposed with differential
interference contrast (DIC) images in a 72-hour specimen showed that matrilysin staining was localized to epithelium of distal tubule/collecting
duct origin (arrows). Original magnification: D–F, 10×, G–I, 40×.
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Fig. 4. Matrilysin expression is induced by acute unilateral ureteral ob-
struction (UUO) in the mouse and expression increases as obstruction
continues. Northern blot analysis for matrilysin in total kidney RNA
isolated from mice at 24 hours to 5 days after complete UUO of left
kidney. Ethidium bromide stained 18S and 28S rRNA are shown as a
loading control. Mouse small intestine (SI) is shown as positive control.
In mice that develop renal fibrosis after folic acid treat-
ment, Wnt4 expression peaks at 14 days after injury [15].
At 16 days after folic acid treatment, in situ hybridiza-
tion for matrilysin and Wnt4 identified a patchy pattern
of mRNA expression consistent with the focal nature of
folic acid injury (Fig. 6E). Similar to what was found for
UUO, matrilysin mRNA was expressed in the same ar-
eas and in a nearly identical pattern as Wnt4 after folic
acid–induced renal fibrosis (Fig. 6F). Higher magnifica-
tion views of serial sections of a kidney 16 days after folic
acid treatment indicated that Wnt4 was expressed mainly
in interstitial cells adjacent to matrilysin expressing ep-
ithelial cells in damaged tubules (Fig. 6G and H). Collec-
tively, these data indicate that Wnt4 expression correlates
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Fig. 5. Induction of matrilysin expression in relation to Wnt4 after experimental renal tubular injury. Steady-state matrilysin and Wnt4 mRNA
levels were determined by RNAse protection assays (RPA) at various times after UUO. Five micrograms of total RNA extracted from the obstructed
kidneys of FVB/N mice were used in the assays, and three separate animals were assayed at each time point. (A) MMP-7 assay (arrow), (B) Wnt4
assay (arrow). Both assays included probes for the ubiquitous cyclophilin A gene transcript as an internal control (arrow labeled CYCL). The
undigested radiolabeled antisense riboprobes were included on each gel: MMP-7 (A, lane m), Wnt4 (B, lane w), and CYCL (A and B, lane y).
Assays shown in the corresponding lanes of panels (A) and (B) were performed using the same RNA samples. (C) Graphical representation of the
time course of matrilysin and Wnt4 induction shown as ratios of the intensity of MMP-7 (solid line) or Wnt4 (dashed line) signal to that of cyclophilin
A (mean ratios ± SD). (D) RT-PCR for matrilysin (MMP-7), Wnt4, and b-actin performed on total RNA isolated from C57Bl6 mice up to 6 days
after folic acid injury.
with that of matrilysin in two models of renal tubular in-
jury in both strains of mice evaluated.
Cystic degeneration is characterized by renal tubular
epithelial damage, interstitial fibrosis, and loss of renal
function. Our previous studies found that Wnt4 was acti-
vated in jck mice [15], in which spontaneous, progressive
epithelial cysts develop [24]. Early in jck cyst formation
Wnt4 is located in cystic epithelium, with a later shift to
pericystic interstitial cells [15]. In situ hybridization for
Wnt4 in kidney of a 16-week-old jck mouse showed that
Wnt4 localized to interstitial cells adjacent to cystic ep-
ithelium (Fig. 7A and D). In situ hybridization for ma-
trilysin in a serial section showed that matrilysin mRNA
was found only in the cyst-lining epithelium immediately
adjacent to the Wnt4 expressing cells (Fig. 7B and E).
As was seen in kidneys from folic acid–treated mice, in
kidneys of jck mice, Wnt4 expression was seen primar-
ily in cells adjacent to matrilysin expressing cells lining
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Fig. 6. Wnt4 and matrilysin have similar spatial expression patterns
after unilateral ureteral obstruction (UUO) and folic acid induced re-
nal injury. RNA in situ hybridization was performed to compare the
spatial expression patterns of Wnt4 and matrilysin. Sections from kid-
neys of FVB/N mice two weeks after UUO (A and B) and 16 days after
folic acid injection (E and F) were hybridized with antisense riboprobes
specific for Wnt4 (A and E) or matrilysin (B and F). Dark field images
illustrate Wnt4 mRNA expression and matrilysin mRNA expression in
strikingly similar patterns on adjacent kidney sections at 14 days af-
ter UUO. Arrows identify the same inner medullary region containing
both Wnt4 and matrilysin mRNA transcripts. Panels (C) and (D) of an
adjacent section show tubular epithelial expression of matrilysin pro-
tein (green) at 14 days after UUO (immunofluorescence superimposed
with DIC). (E and F) illustrate that Wnt4 and matrilysin have a strik-
ingly similar pattern of mRNA expression after folic acid induced renal
fibrosis. Arrows identify the same region containing both Wnt4 and ma-
trilysin mRNA transcripts. (G and H) are higher magnification views of
serial sections from a kidney 16 days after folic acid injection showing
Wnt4 expression in interstitial cells adjacent to matrilysin expressing
epithelial cells in a dilated tubule.
cysts and dilated tubules (Fig. 7F). Immunofluorescence
also localized matrilysin protein to cyst-lining epithelial
cells and dilated tubules (Fig. 7C). Thus, the pattern of
matrilysin expression in this mouse model of cystic kid-
ney disease was similar to that of matrilysin expression in
human ADPKD.
DISCUSSION
The lack of matrilysin expression in uninjured kidneys
in humans and mice, and induction after injury in three
models of experimental renal tubular injury in two strains
of mice, suggests that matrilysin functions in the epithe-
lial responses to injury in the distal nephron. As in other
human and mouse tissues [6, 8, 25], matrilysin expres-
sion was primarily limited to epithelial cells, and was
not prominently expressed in interstitial or inflammatory
cells. That matrilysin was not previously found in the kid-
ney is not surprising. Other MMPs, such as gelatinases-
A and -B (MMP-2 and -9) and stromelysin-1 (MMP-3),
were identified in cultured tubules from cpk cystic mice
kidneys [26] using gelatin zymography, which has low sen-
sitivity for matrilysin [27]. Furthermore, matrilysin may
be tightly bound to cell surface heparan sulfate proteo-
glycans [28], and would not likely be detected in cyst fluid
or in the serum or plasma, as was reported for MMP-1
and MMP-9 in ADPKD [29].
Abnormal ECM accumulation is a common finding
in renal fibrosis and cystic kidney disease [3], and al-
tered matrix degradation may be a factor in renal fibrosis
[30]. Consequently, expression of MMPs and their en-
dogenous inhibitors, the tissue inhibitors of metallopro-
teinases (TIMPs), have been investigated in renal injury.
MMP-2, -14 (MT1-MMP), -3, and -9, as well as TIMP-1
and -2 are variably found in human and animal models of
renal tubular disease [3, 31, 32]. However, specific func-
tions for individual MMPs have not been defined.
Studies in other systems provide insight into how ma-
trilysin may regulate the cellular processes involved in
fibrosis, including apoptosis, inflammation, chronic ep-
ithelial damage, and fibroblast migration and prolifera-
tion [3, 33]. During prostate involution and in pancreatic
acinar to ductal metaplasia, matrilysin can regulate apop-
tosis by cleaving Fas ligand [34, 35]. Matrilysin induced
by acute bleomycin lung injury in the mouse cleaves the
ectodomain of syndecan-1 to shed syndecan/KC-1 com-
plexes and generate a chemotactic gradient that directs
neutrophils into the airspace [36]. In injured airways, ma-
trilysin is secreted basolaterally to mediate shedding of
E-cadherin and reorganization of intercellular junctions
[11]. This is distinct from the constitutive, apical secretion
seen in uninjured human airways and glandular epithe-
lium [8], suggesting that matrilysin is likely targeted to
different substrates in intact versus injured airway ep-
ithelium. Similarly, apical matrilysin localization in at-
rophic tubules and cytoplasmic expression in cyst lining
epithelium suggests that matrilysin may have multiple
substrates and functions in the kidney. Matrilysin can de-
grade many ECM proteins in vitro, including fibronectin
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Fig. 7. In the kidneys of jck mice matrilysin expression is induced in the epithelial cells lining the cysts that are surrounded by Wnt4 expressing
interstitial cells. RNA in situ hybridization was performed to detect matrilysin and Wnt4 expression patterns in 16-week-old jck kidneys. (A) and
(B) are adjacent sections, and (D) and (E) are adjacent sections. (A) Wnt4 mRNA expression is predominantly detected in the interstitial cells
surrounding the tubular epithelial cysts in the jck mice. (B) Matrilysin (MMP-7) mRNA expression is detected predominantly in the epithelial
cells lining the cysts. (C) Immunofluorescence for matrilysin protein is observed in the tubular epithelial cells lining the cysts (arrows). Higher
magnification views of serial sections from a kidney from a 16-week-old jck mouse identify Wnt4 expression (D) in interstitial cells adjacent to
matrilysin expressing epithelial cells (E) surrounding the lumen (Lu) of medullary cysts. (F) Superimposed dark field images of serial sections from
a kidney from a 16-week-old jck mouse with false color added for Wnt 4 (green) and matrilysin (red) indicate that Wnt4 and matrilysin are expressed
in directly adjacent cells.
[27], a prominent component of the provisional matrix in
injured kidneys [33]. However, MMPs are one of several
classes of proteinases that mediate ectodomain shedding
of transmembrane- and membrane-associated proteins
[37], and therefore, secretion to the apical compartment
suggests that the matrilysin substrate(s) in the kidney may
include non-matrix proteins.
Although matrilysin activity is necessary for normal
airway repair, matrilysin is also prominently expressed in
the lung epithelium of patients with pulmonary fibrosis [8,
9], and in liver tissue of patients with chronic hepatitis C
virus and hepatic fibrosis, in which matrilysin expression
correlates with the extent of cirrhosis [38]. Increased ma-
trilysin expression is also seen in experimental bleomycin
lung injury in mice as acute injury progresses to fibrosis
[36]. Similarly, we found matrilysin expression in human
kidney diseases characterized by chronic renal tubular
damage with fibrosis, and in mice that develop fibrosis
after folic acid or UUO; matrilysin mRNA expression
increases and persists as fibrosis progresses. Thus, one
stimulus for persistent matrilysin expression may be the
incomplete or impaired epithelial repair characteristic of
the fibrogenic process.
Although expressed only at low levels in the normal
adult mouse kidney, Wnt4 and other developmentally
regulated genes such as Pax-2 may be re-expressed by ex-
perimental tubular injury [15, 39]. In contrast, matrilysin
is not developmentally expressed in kidney or other or-
gans in mice [5], and kidney development is normal in
matrilysin-null mice [40]. Thus, our data suggest that the
set of genes induced by Wnt-4 signaling in kidney injury
is different from that induced during renal development.
Although matrilysin is a target of the Wnt/b-catenin
signaling pathway in colon cancer [17], a connection
between Wnt signaling and matrilysin expression in the
kidney has not been previously established. In our studies,
the temporal and spatial expression pattern of matrilysin
and Wnt4 suggests that matrilysin expression in the distal
nephron may be directly regulated by Wnt-4. Wnt4 ex-
pression is induced predominantly in interstitial cells sur-
rounding developing renal cysts in jck mice, and in cells
surrounding collecting ducts in areas of tubulointerstitial
fibrosis after folic acid injury or UUO [15]. Matrilysin
expression in immediately adjacent epithelial cells sug-
gests a paracrine effect of interstitial cell derived Wnt-4.
That Wnt4 expression is more broadly distributed than
matrilysin may indicate that Wnt-4 alone is not sufficient
for matrilysin induction, but rather that additional signals
are necessary for matrilysin induction in injured tissue.
Indeed, both b-catenin and the PEA3 subfamily of Ets
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transcription factor signals are necessary for activation of
the matrilysin promoter in vitro [41].
We recently identified that the gene for C-type natri-
uretic peptide (CNP), one of a family of related pep-
tides that regulate fluid and electrolyte homeostasis [43],
is a target of Wnt-4 in renal development and after re-
nal tubular injury [42]. CNP may also limit fibrosis as
exogenous CNP inhibits hepatic myofibroblastic stellate
cell and fibroblast proliferation in vitro [44, 45], and pre-
vents arterial neointimal fibrosis and glomerular fibrosis
in vivo [46–48]. Thus, Wnt-4 may function to limit fibro-
sis by regulating CNP expression in renal interstitial fi-
broblasts and promote re-epithelialization by inducing
matrilysin expression in tubular epithelium. However, a
chronic injury such as UUO may provide a stimulus for
continued Wnt4 expression that may then induce ongo-
ing matrilysin expression. It will be important to evaluate
patterns of Wnt4 and matrilysin expression in less severe
models of renal tubular damage, such as reversible UUO
[49].
CONCLUSION
Matrilysin is expressed in human renal tubular disease
and in mouse models of acute renal tubular injury and
fibrosis, and matrilysin expression temporally and spa-
tially correlates with that of Wnt4. We propose that ma-
trilysin may initially function in tubular epithelial repair,
but that in chronic tubular injury, Wnt4 stimulates per-
sistent matrilysin expression that may then contribute to
renal tubular pathology. We are now exploring how Wnt4
and matrilysin may regulate progression of renal fibrosis.
NOTE ADDED IN PROOF
Consistent with our findings of matrilysin protein ex-
pression in human samples of hydronephrosis, Henger
et al recently reported increased expression of matrilysin
transcripts in human kidney RNA samples from patients
with hydronephrosis and tubulointerstitial inflammation
(Kidney Int 65:904–917, 2004).
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